Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RUFINA P MIEL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1063470391
CMS profile
275605
Location
FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$27,880.94

342 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $16,355.00 8
Food and Beverage $10,135.60 324
Travel and Lodging $719.04 3
Long term medical supply or device loan $498.50 5
Education $172.80 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $11,667.97 20
Gilead Sciences, Inc. $4,948.26 16
GlaxoSmithKline, LLC. $1,836.80 14
Janssen Biotech, Inc. $1,633.83 30
Novartis Pharmaceuticals Corporation $1,009.85 26
Takeda Pharmaceuticals U.S.A., Inc. $599.78 16
PFIZER INC. $547.95 18
Merck Sharp & Dohme LLC $505.97 18
Incyte Corporation $434.78 16
Secura Bio, Inc. $428.34 4
Eisai Inc. $353.54 15
Daiichi Sankyo Inc. $339.42 11
SOBI, INC $272.39 10
GENZYME CORPORATION $252.38 6
Lilly USA, LLC $244.22 8
E.R. Squibb & Sons, L.L.C. $236.15 13
ARRAY BIOPHARMA INC $203.14 11
EMD Serono, Inc. $197.94 6
Celgene Corporation $190.42 10
Astellas Pharma US Inc $141.22 5
Genentech USA, Inc. $137.91 6
PharmaEssentia USA Corporation $110.51 3
Sumitomo Pharma America, Inc. $106.32 5
TAIHO ONCOLOGY, INC. $103.49 4
Menarini Silicon Biosystems, Inc. $102.44 1
Karyopharm Therapeutics Inc. $99.03 4
ABBVIE INC. $94.78 4
Regeneron Healthcare Solutions, Inc. $92.63 3
JAZZ PHARMACEUTICALS INC. $89.80 3
Agios Pharmaceuticals, Inc. $77.44 3
PUMA BIOTECHNOLOGY, INC. $75.07 3
Stemline Therapeutics Inc. $73.56 3
Exelixis Inc. $71.23 2
BeiGene USA, Inc. $63.19 2
Mirati Therapeutics, Inc. $50.14 2
Bayer Healthcare Pharmaceuticals Inc. $49.31 2
Boehringer Ingelheim Pharmaceuticals, Inc. $48.11 2
Ipsen Biopharmaceuticals, Inc $43.02 2
Myriad Genetic Laboratories, Inc. $41.43 2
Alexion Pharmaceuticals, Inc. $34.66 1
ADC Therapeutics America, Inc. $29.52 1
Tempus AI, Inc $27.80 1
Apellis Pharmaceuticals, Inc. $27.28 1
Legend Biotech USA Inc. $26.79 1
Rigel Pharmaceuticals, Inc. $25.20 1
Fennec Pharmaceuticals, Inc. $23.43 1
Deciphera Pharmaceuticals Inc. $23.11 1
Coherus Biosciences Inc. $19.52 1
Novocure Inc. $18.36 1
Chiesi USA, Inc. $17.43 1
Pharmacosmos Therapeutics Inc. $17.36 1
SERVIER PHARMACEUTICALS LLC $16.72 1

Page 2 of 7; records 51–100 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RUFINA P MIEL

NPI 1063470391 · CMS profile ID 275605

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063470391?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RUFINA P MIEL, NPI 1063470391, CMS profile ID 275605. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063470391?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RUFINA P MIEL, NPI 1063470391, CMS profile ID 275605. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063470391?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RUFINA P MIEL, NPI 1063470391, CMS profile ID 275605, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1063470391?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

342 matching records · $27,880.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 342 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 342.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $3.8510/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120272842 CMS
GlaxoSmithKline, LLC. $21.7810/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116003177 CMS
Janssen Biotech, Inc. $25.5210/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078295843 CMS
Celgene Corporation $6.5810/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101169800 CMS
Janssen Biotech, Inc. $125.6410/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078295885 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.9310/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144963142 CMS
E.R. Squibb & Sons, L.L.C. $9.0010/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101664489 CMS
GlaxoSmithKline, LLC. $1,300.0010/25/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211941757 CMS
Incyte Corporation $14.3010/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141297784 CMS
Incyte Corporation $2.9710/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141321873 CMS
Janssen Biotech, Inc. $148.6410/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078295877 CMS
Lilly USA, LLC $14.2410/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135367108 CMS
AstraZeneca Pharmaceuticals LP $83.0410/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104207625 CMS
AstraZeneca Pharmaceuticals LP $2,497.5010/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105659096 CMS
AstraZeneca Pharmaceuticals LP $23.5010/23/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155834452 CMS
JAZZ PHARMACEUTICALS INC. $29.6610/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150197556 CMS
Merck Sharp & Dohme LLC $14.6010/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141728540 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.3010/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144963140 CMS
TAIHO ONCOLOGY, INC. $22.7010/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137936291 CMS
Stemline Therapeutics Inc. $27.9210/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963696 CMS
Janssen Biotech, Inc. $19.5610/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078295737 CMS
Novartis Pharmaceuticals Corporation $99.7010/17/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087047172 CMS
PFIZER INC. $29.3610/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131369746 CMS
Janssen Biotech, Inc. $2.2610/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078295903 CMS
Lilly USA, LLC $21.0810/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135340003 CMS
SOBI, INC $121.0010/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141436985 CMS
Merck Sharp & Dohme LLC $22.5510/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141879323 CMS
Eisai Inc. $33.1710/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110778367 CMS
Eisai Inc. $31.9710/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110778369 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.6910/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086165302 CMS
Merck Sharp & Dohme LLC $34.2010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141728702 CMS
PFIZER INC. $124.9910/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132000713 CMS
E.R. Squibb & Sons, L.L.C. $4.9610/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101664493 CMS
Incyte Corporation $65.0010/07/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141293916 CMS
Incyte Corporation $24.6510/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141297410 CMS
AstraZeneca Pharmaceuticals LP $78.1410/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104324714 CMS
AstraZeneca Pharmaceuticals LP $179.6710/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105562228 CMS
AstraZeneca Pharmaceuticals LP $17.6610/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105647594 CMS
Novartis Pharmaceuticals Corporation $27.3610/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087047168 CMS
PFIZER INC. $25.4710/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131374306 CMS
GlaxoSmithKline, LLC. $29.2810/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115910446 CMS
Merck Sharp & Dohme LLC $17.7210/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141934877 CMS
Astellas Pharma US Inc $27.6909/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139421491 CMS
Regeneron Healthcare Solutions, Inc. $37.5009/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114114953 CMS
Novartis Pharmaceuticals Corporation $99.7009/27/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087047166 CMS
Eisai Inc. $29.1709/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110778343 CMS
PUMA BIOTECHNOLOGY, INC. $23.7909/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113845413 CMS
SOBI, INC $19.7009/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141432155 CMS
Mirati Therapeutics, Inc. $25.9209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117174361 CMS
ABBVIE INC. $23.7809/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105032665 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,946.49 175
PY2020 $14,073.21 188
PY2021 $6,900.58 224
PY2022 $7,037.78 253
PY2023 $13,445.95 275
PY2024 $27,880.94 342
PY2025 $29,256.95 293

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $206,586.26 51
PY2024 Principal investigator $144,332.45 25
PY2023 Principal investigator $146,338.86 12
PY2022 Principal investigator $47,186.00 4
PY2021 Principal investigator $9,137.86 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $72.90 11/12/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739957
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,505.00 11/12/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739959
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $250.00 11/12/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739961
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,505.00 11/12/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739963
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $155.25 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739951
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $155.25 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739953
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,474.00 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739955
Principal investigator 1 Novartis Pharmaceuticals Corporation $111.72 10/28/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190312481
Principal investigator 1 Genentech, Inc. $250.00 09/24/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673044
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $155.25 09/19/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739943
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $228.15 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739945
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $250.00 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739947
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $310.50 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739949
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,330.00 09/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739941
Principal investigator 1 Janssen Research & Development, LLC $900.00 09/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175168877
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,729.80 08/15/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739935
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,080.00 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739931
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $60.75 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739933
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,389.15 08/13/2025 Non-covered Recipient Entity
HELIOS CR INC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739937
Principal investigator 1 Genentech, Inc. $7,004.00 08/06/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673011
Principal investigator 1 Genentech, Inc. $5,528.00 08/06/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673027
Principal investigator 1 Genentech, Inc. $2,960.00 08/06/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673037
Principal investigator 1 Genentech, Inc. $592.00 08/04/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672998
Principal investigator 1 Genentech, Inc. $296.00 08/04/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673019
Principal investigator 1 Genentech, Inc. $2,395.00 07/29/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672989
Principal investigator 1 Genentech, Inc. $7,652.18 07/11/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673015
Principal investigator 1 Genentech, Inc. $10,963.00 07/10/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673032
Principal investigator 1 Genentech, Inc. $100.00 07/08/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673007
Principal investigator 1 Genentech, Inc. $250.00 07/03/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672993
Principal investigator 1 Genentech, Inc. $250.00 07/03/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673002
Principal investigator 1 Genentech, Inc. $100.99 07/03/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211673022
Principal investigator 1 Genentech, Inc. $296.00 07/02/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672924
Principal investigator 1 Genentech, Inc. $13,419.62 07/02/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672927
Principal investigator 1 Novartis Pharmaceuticals Corporation $42,727.29 07/01/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190312485
Principal investigator 1 Genentech, Inc. $55.71 06/11/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672916
Principal investigator 1 Genentech, Inc. $296.00 05/28/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672919
Principal investigator 1 Genentech, Inc. $6,202.00 05/21/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672930
Principal investigator 1 Genentech, Inc. $12,261.80 05/20/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672973
Principal investigator 1 Genentech, Inc. $1,719.00 04/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672961
Principal investigator 1 Genentech, Inc. $99.62 04/16/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672965
Principal investigator 1 Genentech, Inc. $15,174.00 04/09/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672983
Principal investigator 1 Genentech, Inc. $95.75 04/08/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672933
Principal investigator 1 Genentech, Inc. $263.00 04/08/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672936
Principal investigator 1 Genentech, Inc. $1,462.00 04/08/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672951
Principal investigator 1 Genentech, Inc. $263.00 04/08/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672976
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $15,675.00 04/02/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745184
Principal investigator 1 Genentech, Inc. $92.79 03/26/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672957
Principal investigator 1 Genentech, Inc. $468.00 03/20/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672939
Principal investigator 1 Genentech, Inc. $2,015.00 03/20/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672946
Principal investigator 1 Genentech, Inc. $378.49 03/20/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211672969
Principal investigator 1 Karyopharm Therapeutics Inc. $6,618.30 01/30/2025 Non-covered Recipient Entity
Innovative Clinical Research Institute, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246663595